Updated

ORIC Pharmaceuticals (ORIC) is doubling down on its prostate cancer treatment pipeline with the launch of a Phase 3 clinical trial, marking a significant step in the company's late-stage development efforts. The move reflects growing investor and industry interest in the company's oncology-focused pipeline. The trial launch is seen as a key catalyst for the stock, with the company betting heavily on the drug's potential to address unmet needs in prostate cancer treatment.